Data Characteristics
Small molecule drug pharmacovigilance data originates from clinical trial reports, real-world evidence (RWE) data, post-market surveillance reports, and global adverse drug reaction databases (e.g., FDA Adverse Event Reporting System, FAERS). These data sources update frequently. Clinical trial data releases occur incrementally with trial progress. Post-market surveillance reports typically update quarterly or annually. Document structures vary, including structured Case Report Forms (CRF), semi-structured free-text adverse event descriptions, and unstructured medical literature and patient feedback. Fields include patient demographics, medication history, adverse event descriptions (symptoms, signs, onset time, outcome), drug information (brand name, generic name, batch number, dosage, usage), and relevant lab results. Adverse event severity and causality assessments often use standardized terminology (e.g., MedDRA codes) or free text.
Constraints from Data Characteristics on Model Integration and Configuration
The complexity and diversity of small molecule drug data sources require robust multimodal processing capabilities during model integration. Medical terminology, abbreviations, and colloquial expressions in free-text descriptions demand high accuracy in text preprocessing and entity recognition. High-frequency data updates mean the knowledge base must support incremental updates and version management to ensure models always reason with the latest information. The mix of structured and unstructured data necessitates fine-grained structured extraction and knowledge graph construction during data ingestion, such as linking adverse event symptoms to drug mechanisms of action. Furthermore, the rigor of pharmacovigilance requires model output interpretability and traceability. Configure parameters to ensure comprehensive recall and support referencing original documents.
Configuration Guidelines
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk size (Segment Length) | 500-800 characters (characters) | Accommodates adverse event description length, balancing context completeness and model processing efficiency. |
Overlap Length | 100-150 characters (characters) | Ensures key information association across segments, preventing context breaks. |
Recall count (Recall Count) | 8-12 entries (items) | Covers diverse adverse event reports and relevant medical literature, improving recall comprehensiveness. |
Similarity threshold (Similarity Threshold) | 0.75-0.85 | Balances relevance and noise, avoiding recall of irrelevant or overly broad document segments. |
PARSE_FILE_TIMEOUT_SECONDS | 300 seconds (seconds) | Handles parsing time for large clinical trial reports or PDF documents, preventing timeout interruptions. |
Knowledge Base Refresh Frequency | daily or weekly | Matches the high update frequency of pharmacovigilance data, maintaining knowledge base timeliness. |
Common Configuration Mistakes
- The model fails to respond to uploaded clinical trial reports or post-market surveillance documents. This occurs when
PARSE_FILE_TIMEOUT_SECONDSis set too low, causing document parsing to time out. - Model results do not cover all relevant adverse event information. This may happen if
Recall count(Recall Count) is set too low, failing to retrieve sufficient context from the knowledge base. - During knowledge base Q&A, the model fails to effectively use the latest adverse drug reaction data. This indicates an incorrect knowledge base update mechanism or improper
Knowledge Base Refresh Frequencyconfiguration.
Validation Steps
- Upload typical adverse event report documents. Verify the model correctly parses and extracts key adverse event and drug information.
- Query the model about known adverse reactions for a specific small molecule drug. Check if the model recalls and synthesizes multiple relevant document segments from the knowledge base.
- Compare the model's response to newly released adverse reaction data with its response to older data. Ensure the model reasons based on the latest information after a knowledge base refresh.
The values provided are common starting points. Measure them against your own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.